Clinical Trial Update: A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001 [Phase 1]

View source ↗

Summary

EpicentRx conducted a Phase 1 pilot study of subcutaneous administration of RRx-001 for malignant solid tumors and lymphomas, which has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumor

Drugs mentioned

• RRx-001

Snippet

Sponsor: EpicentRx, Inc. | Conditions: Malignant Solid Tumor, Lymphomas | Phase 1 | Status: TERMINATED